|

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

RECRUITINGSponsored by Miltenyi Biomedicine GmbH
Actively Recruiting
SponsorMiltenyi Biomedicine GmbH
Started2024-05-15
Est. completion2041-12-01
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations11 sites

Summary

This is an observational long-term follow-up (LTFU) study for subjects who previously received zamtocabtagene autoleucel, known as MB-CART2019.1.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Received zamtocabtagene autoleucel in a North American Miltenyi Biomedicine-sponsored clinical study and have not withdrawn consent to be followed or been deemed lost to follow-up.
* Provided written informed consent to participate in this study.

Exclusion Criteria:

* None

Conditions7

CancerCentral Nervous System LymphomaHigh-grade B-cell LymphomaNon-hodgkin LymphomaPrimary Mediastinal B-cell Lymphoma (PMBCL)Refractory Diffuse Large B-cell Lymphoma (DLBCL)Relapsed Diffuse Large B Cell Lymphoma

Locations11 sites

Banner MD Anderson Cancer Center
Gilbert, Arizona, 85234
Stanford University
Stanford, California, 94305
Christina Tranctran13@stanford.edu
Yale University
New Haven, Connecticut, 06520
Robert H Lurie Cancer Center
University of Kansas Cancer Center
Westwood, Kansas, 66205
Sunil Abhyankar, MDsabhyankar@kumc.edu

Find trials near these locations

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.